Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4821-4827

  Tafin, Ulrika Furustrand ^a   Majic, Ivana ^b   Zalila, Cyrine Belkhodja ^a   Betrisey, Bertrand ^a   Corvec, Stéphane ^a,c   Zimmerli, Werner ^d   Trampuz, Andrej ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Kantonsspital Liestal   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; GENTAMICIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BROTH DILUTION; CAGE; COLONY FORMING UNIT; CONTROLLED STUDY; DEVICE INFECTION; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; INOCULATION; MALE; MAXIMUM PLASMA CONCENTRATION; MICROCALORIMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THERMOGENESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECALIS; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; GUINEA PIGS; MALE; MICROBIAL SENSITIVITY TESTS; PROSTHESIS-RELATED INFECTIONS; VANCOMYCIN;

EID: 80052851453     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00141-11     Document Type: Article

References (42)

1. Baldoni, D., M. Haschke, Z. Rajacic, W. Zimmerli, and A. Trampuz. 2009. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents Chemother. 53:1142-1148.
2. Baldoni, D., H. Hermann, R. Frei, A. Trampuz, and A. Steinhuber. 2009. Performance of microcalorimetry for early detection of methicillin resistance in clinical isolates of Staphylococcus aureus. J. Clin. Microbiol. 47:774-776.
3. Baldoni, D., A. Steinhuber, W. Zimmerli, and A. Trampuz. 2010. In vitro activity of gallium maltolate against Staphylococci in logarithmic, stationary, and biofilm growth phases: comparison of conventional and calorimetric susceptibility testing methods. Antimicrob. Agents Chemother. 54:157-163.
4. Benvenuto, M., D. P. Benziger, S. Yankelev, and G. Vigliani. 2006. Pharma-cokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249.
5. Blaser, J., P. Vergeres, A. F. Widmer, and W. Zimmerli. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139.
6. Braissant, O., D. Wirz, B. Gopfert, and A. U. Daniels. 2010. Use of isothermal microcalorimetry to monitor microbial activities. FEMS Microbiol. Lett. 303:1-8.
7. Bridier, A., F. Dubois-Brissonnet, A. Boubetra, V. Thomas, and R. Briandet. 2010. The biofilm architecture of sixty opportunistic pathogens deciphered using a high throughput CLSM method. J. Microbiol. Methods 82:64-70.
8. Bush, L. M., J. A. Boscia, and D. Kaye. 1988. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 32:877-881.
9. Canton, R., P. Ruiz-Garbajosa, R. L. Chaves, and A. P. Johnson. 2010. A potential role for daptomycin in enterococcal infections: what is the evidence? J. Antimicrob. Chemother. 65:1126-1136.
10. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline, M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement, M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
13. Dvorchik, B. H., D. Brazier, M. F. DeBruin, and R. D. Arbeit. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323.
14. El Helou, O. C. et al. 2008. Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy? Clin. Infect. Dis. 47:903-909.
15. Fabretti, F., and J. Huebner. 2005. Implant infections due to enterococci: role of capsular polysaccharides and biofilm. Int. J. Artif. Organs 28:1079-1090.
16. John, A. K. et al. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724.
17. Kristich, C. J., C. L. Wells, and G. M. Dunny. 2007. A eukaryotic-type Ser/Thr kinase in Enterococcus faecalis mediates antimicrobial resistance and intestinal persistence. Proc. Natl. Acad. Sci. U. S. A. 104:3508-3513.
18. Lefort, A. et al. 2000. Bactericidal activity of gentamicin against Enterococcus faecalis in vitro and in vivo. Antimicrob. Agents Chemother. 44:2077-2080.
19. Liu, C. et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
20. Mohamed, J. A., and D. B. Huang. 2007. Biofilm formation by enterococci. J. Med. Microbiol. 56:1581-1588.
21. Palmer, K. L., A. Daniel, C. Hardy, J. Silverman, and M. S. Gilmore. 2011. Genetic basis for daptomycin resistance in enterococci. Antimicrob. Agents Chemother. 55:3345-3356.
22. Phillips, J. E., T. P. Crane, M. Noy, T. S. Elliott, and R. J. Grimer. 2006. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. J. Bone Joint Surg. Br. 88:943-948.
23. Sandoe, J. A. et al. 2002. Enterococcal intravascular catheter-related bloodstream infection: management and outcome of 61 consecutive cases. J. Antimicrob. Chemother. 50:577-582.
24. Sandoe, J. A., J. Wysome, A. P. West, J. Heritage, and M. H. Wilcox. 2006. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J. Antimicrob. Chemother. 57:767-770.
25. Sava, I. G., E. Heikens, and J. Huebner. 2010. Pathogenesis and immunity in enterococcal infections. Clin. Microbiol. Infect. 16:533-540.
26. Sava, I. G. et al. 2010. Enterococcal surface protein contributes to persistence in the host but is not a target of opsonic and protective antibodies in Enterococcus faecium infection. J. Med. Microbiol. 59:1001-1004.
27. Stewart, P. S., and J. W. Costerton. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
28. Trampuz, A., S. Salzmann, J. Antheaume, and A. U. Daniels. 2007. Microcalorimetry: a novel method for detection of microbial contamination in platelet products. Transfusion 47:1643-1650.
29. Trampuz, A., A. Steinhuber, M. Wittwer, and S. L. Leib. 2007. Rapid diagnosis of experimental meningitis by bacterial heat production in cerebrospinal fluid. BMC Infect. Dis. 7:116.
30. Trampuz, A. et al. 2007. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob. Agents Chemother. 51:2540-2545.
31. Trampuz, A., and A. F. Widmer. 2006. Infections associated with orthopedic implants. Curr. Opin. Infect. Dis. 19:349-356.
32. Vergidis, P. et al. 2011. Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. Antimicrob. Agents Chemother. 55:1182-1186.
33. von Ah, U., D. Wirz, and A. U. Daniels. 2009. Isothermal micro calorimetry - a new method for MIC determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus. BMC Microbiol. 9:106.
34. Widmer, A. F., R. Frei, Z. Rajacic, and W. Zimmerli. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162:96-102.
35. Widmer, A. F., A. Gaechter, P. E. Ochsner, and W. Zimmerli. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-1253.
36. Widmer, A. F., A. Wiestner, R. Frei, and W. Zimmerli. 1991. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob. Agents Chemother. 35:741-746.
37. Wise, R., T. Gee, J. M. Andrews, B. Dvorchik, and G. Marshall. 2002. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob. Agents Chemother. 46:31-33.
38. Woodford, N. et al. 2002. Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis. J. Clin. Microbiol. 40:4298-4300.
39. Zimmerli, W., R. Frei, A. F. Widmer, and Z. Rajacic. 1994. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33:959-967.
40. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
41. Zimmerli, W., F. A. Waldvogel, P. Vaudaux, and U. E. Nydegger. 1982. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 146:487-497.
42. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, P. E. Ochsner, et al. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 279:1537-1541. (Pubitemid 28233008)